REFERENCES
- Hamilton A., Piccart M. The Third Generation Non-steroidal Aromatase Inhibitors: A Review of Their Clinical Benefits in the Second-Line Hormonal Treatment of Advanced Breast Cancer. Ann. Oncol. 1999; 10: 377–384
- Skubitz K. Phase II Trial of Peglyated-Liposomal Doxorubicin (Doxil™) in Mesothelioma. Cancer Investig. 2002; 20(5&6)693–699
- Herbst R.S., Lee A.T., Tran H.T., Abbruzzese J.L. Clinical Studies of Angiogenesis Inhibitors: The University of Texas MD Anderson Center Trial of Human Endostatin. Curr. Oncol. Rep. 2001; 3(2)131–140
- Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G., Giavazzi R., Taraboletti G. The Microtubule-Affecting Drug Paclitaxel Has Antiangiogenic Activity. Clin. Cancer Res. 1996; 2(11)1843–1849
- Rocca A., Colleoni M., Masci G., Orlando L., Peruzzotti G., Nole F., de Braud F., Robertson C., Goldhirsch A. Low Dose Oral Methotrexate (MTX) and Cyclophosphamide (CTX) in Metastatic Breast Cancer (MBC): An Attempt to Exploit the Antiangiogenic Activity of Common Chemotherapeutic Agents. Proc. Am. Soc. Clin. Oncol. 2001; 20: 30a, (abstr #116)
- Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged Circulation Time and Enhanced Accumulation in Malignant Exudates of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol Coated Liposomes. Cancer Res. 1994; 54(4)987–992
- Uziely B., Groshen S., Jeffers S., Morris M., Russell C., Roman L., Muderspach L., Muggia F.M. Paclitaxel (Taxol) in Heavily Pretreated Ovarian Cancer: Antitumor Activity and Complications. Ann. Oncol. 1994; 5: 827–833
- Muggia F.M., Hainsworth J., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F.A., Morrow C.P., Paradiso L.J., Liang L.-J. Phase II Study of Doxil in Refractory Ovarian Cancer: Antitumor Activity and Toxicity Modification by Liposomal Encapsulation. J. Clin. Oncol. 1997; 15: 987–993
- Safra T., Groshen S., Jeffers S., Tsao-Wei D.D., Zhou L., Muderspach L., Roman L., Morrow C.P., Burnett A., Muggia F.M. Treatment of Patients with Ovarian Carcinoma with Pegylated Liposomal Doxorubicin: Analysis of Toxicities and Predictors of Outcome. Cancer 2001; 91: 90–100
- Gabizon A.A. Selective Tumor Localization and Improved Therapeutic Index of Anthracyclines Encapsulated in Long-Circulating Liposomes. Cancer Res. 1992; 52: 891–896
- Gordon A., Fleagle J.T., Guthrie D., Parkin D.E., Gore M., Lacave A.J., Mutch D. Interim Analysis of a Phase III Randomized Trial of Doxil/Caclyx (D) versus Topotecan (T) in the Treatment of Patients with Relapsed Ovarian Cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19, abstract 1504
- Safra T., Muggia F., Jeffers S., Tsao-Wei D.D., Groshen S., Lyass O., Henderson R., Berry G., Gabizon A. Pegylated Liposomal Doxorubicin (Doxil): Reduced Clinical Cardiotoxicity in Patients Reaching or Exceeding Cumulative Doses of 500 mg/m2. Ann. Oncol. 2000; 11: 1029–1033